Fax: (011) 33-478-78-27-16.
A phase 2 trial of whole-brain radiotherapy combined with intravenous chemotherapy in patients with brain metastases from breast cancer
Article first published online: 8 SEP 2008
Copyright © 2008 American Cancer Society
Volume 113, Issue 9, pages 2532–2538, 1 November 2008
How to Cite
Cassier, P. A., Ray-Coquard, I., Sunyach, M.-P., Lancry, L., Guastalla, J.-P., Ferlay, C., Gomez, F., Curé, H., Lortholary, A., Claude, L., Blay, J.-Y. and Bachelot, T. (2008), A phase 2 trial of whole-brain radiotherapy combined with intravenous chemotherapy in patients with brain metastases from breast cancer. Cancer, 113: 2532–2538. doi: 10.1002/cncr.23858
- Issue published online: 17 OCT 2008
- Article first published online: 8 SEP 2008
- Manuscript Accepted: 19 MAY 2008
- Manuscript Revised: 26 MAR 2008
- Manuscript Received: 3 JAN 2008
- Pierre Fabre Oncologie France
- Ligue Nationale de Lutte Contre le Cancer
- brain metastases;
- breast cancer;
- whole brain radiation therapy
A study was conducted to determine the efficacy, tolerability, and safety of concurrent cisplatin and vinorelbine chemotherapy and radiotherapy in patients with previously untreated brain metastases from breast cancer.
Twenty-five patients with untreated brain metastases from breast cancer were treated with cisplatin (at a dose of 20 mg/m2/day, Days 1-5) and vinorelbine (6-mg/m2 bolus on Day 1 and 6 mg/m2/day continuous infusion on Days 1-5) chemotherapy combined with concurrent 30-gray fractionated external-beam radiotherapy. Chemotherapy was given at 3-week intervals for a total of 4 cycles. Primary endpoint was the rate of radiologic response of brain metastases.
Complete response in the brain was observed in 3 patients, and partial response was noted in 16 patients, yielding a 76% response rate in the brain. The overall systemic response rate was 44%. Progression-free and overall survival were 3.7 months and 6.5 months, respectively. Overall toxicity was acceptable; nonhematologic grade 3-4 events were noted in 5 (20%) patients, and there were no toxic deaths.
Concurrent chemoradiation with cisplatin and vinorelbine for brain metastases from breast cancer appears to be active and well tolerated. Cancer 2008. © 2008 American Cancer Society.